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ate public health policies address the affordability of antimalari-
als; it is unlikely that there will be any reduction in malaria
morbidity and mortality in the poor.
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OBJECTIVES: To evaluate the cost-effectiveness of implement-
ing a universal infant 7-valent pneumococcal conjugate vaccine
(PCV7) programme in the Irish health care setting. METHODS:
A model was constructed to follow a cohort of vaccinated and
unvaccinated individuals from birth over a 10 year period. The
number of life years gained (LYG) from the vaccination pro-
gramme was the primary outcome. The model was constructed
using MS Excel and was run in 6 monthly cycles with the excep-
tion of the ﬁrst year of age, which was divided into three age
bands: 0–2 months, 2–6 months and 6–12 months. Incidence
data, vaccine efﬁcacy and background mortality were based on
national data and/or published evidence. A cost of illness esti-
mate for each pneumococcal infection was determined using
decision tree analysis that considered direct costs only. The
reduction in events that would be associated with PCV7 vacci-
nation and the mortality and cost resulting from these events
were analysed. In a separate sub-model the effect of herd immu-
nity was investigated where it was assumed that indirect protec-
tion would be conferred on the unvaccinated adult population
for a period of one year. RESULTS: Implementing a PCV7 vac-
cination programme in Ireland in a birth cohort of 61,000 infants
would be expected to prevent 7,703 cases of pneumococcal
related infections over 10 years, resulting in savings of €2.05
million, increasing to €4.6 million if the effect of herd immunity
is included. The baseline ICER is €98,279/LYG which reduces to
€3,162/LYG when the effect of herd immunity is included. CON-
CLUSION: Universal infant pneumococcal conjugate vaccina-
tion could be considered highly cost-effective in the Irish health
care setting from a health care payers perspective, if viewed in
terms of the herd immunity effect. The results of this study have
positive ramiﬁcations for countries in the early stages of health
technology assessment.
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OBJECTIVES: To understand the infrastructure for HLA-
B*5701 screening within the UK and establish the direct cost of
correctly screening patients. METHODS: Presence of the HLA-
B*5701 allele is associated with predisposition for hypersensitiv-
ity to abacavir (KivexaTM, GSK). Some HIV clinicians routinely
screen patients for HLA-B*5701 prior to prescribing abacavir.
The characteristics and relative costs of available screening
methods are therefore integral to the impact of screening on
cost-effectiveness of abacavir in practice. Yet this information is
poorly understood. No deﬁnitive reference cost is available and
screening is provided by many laboratory services, to varying
speciﬁcations and at different cost. Obtaining robust data there-
fore required a creative approach. Extensive planned research
with clinicians and the sales force informed the content and
structure of the audit. Interviews were conducted with 25 major
HIV centres (currently screening patients for HLA-B*5701 prior
to initiation of abacavir therapy), and an advisory board with
expert panellists was undertaken during 2006. Methodologies
used by different laboratories were explored (with laboratory
personnel if necessary) to determine whether screening of sufﬁ-
cient resolution was provided. RESULTS: The audit found three
regional networks of laboratories providing genetic screening
services to hospitals on a local and national basis. Hospitals
routinely accessed different laboratories for different clinical
services. Result turnaround times varied from 5 to 14 days,
although most laboratories could provide an immediate (2 hour)
service if required. The cost of screening varied between 35–90
GBP. Costs were minimised in larger laboratories predominantly
through using the latest technologies, batching samples, short
transport distances and the use of blood sample aliquots already
extracted for other tests. CONCLUSION: UK HIV clinicians
have routine access to screening technologies for 4-digit resolu-
tion of HLA-B*5701 that are affordable, quality assured and
rapid. The impact of this information on the cost effectiveness of
abacavir is the subject of ongoing research.
INFECTION—Methods and Concepts
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OBJECTIVES: To estimate from the national database of hos-
pital admissions in 2005, the economic burden in France of
febrile neutropenia (FN) associated with myelosuppressive che-
motherapy. METHODS: In France, public and private hospital
admissions are recorded in administrative databases that gen-
erate Diagnosis Related Groups (DRGs), ICD10 diagnosis and
procedure codes. Admissions with FN were extracted with
codes combining cancer, chemotherapy, and drug-induced neu-
tropenia. These were then categorized into those with a prin-
cipal diagnosis of FN, those in which FN prolonged length of
stay, and those where planned treatments were cancelled due to
FN. The costs of admissions to public hospitals were obtained
from an annual study of a sample group of institutions. This
study is also used to generate charges to the payer (ofﬁcial
DRG tariffs). Costs in private clinics were estimated with the
2004 reimbursement database, to which medical fees were
added. Charges to the health care system were estimated with
the ofﬁcial 2007 DRG tariffs. RESULTS: In 2005, the total
number of patient admissions meeting selection criteria was
38,266 i.e. 3% of all admissions for chemotherapy. Of these,
41% were due to FN, 56% were prolonged hospitalizations
because of FN and 3% were procedures cancelled due to FN.
In public hospitals, the mean cost per admission due to FN was
€3636 (n = 13,923), mean charge was €3565. In private hospi-
tals, this cost was €1930 per admission (n = 1517). For inpa-
tient admissions to public hospitals alone (n = 9444), the mean
cost was €5030, mean charge €4931. Total cost to the payer
for public and private admissions was €54 million i.e. 3% of
the total cost for chemotherapy in France. CONCLUSION:
Administrative databases can be used to estimate the economic
burden of FN, a frequent complication of chemotherapy. They
could be a relevant tool for studying the potential cost savings
derived from appropriate preventive use of colony-stimulating
factors.
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